Last month, Anaheim pharma giant Eli Lilly & Co. announced that it will stop development of experimental cholesterol drug evacetrapib, which could mean good news for Thousand Oaks biotech Amgen Inc. ...

Subscribe to get the full story.


Are you a subscriber? Sign In